ImmuCell Corp (ICCC) income statement
ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/301% above fair value
$10.92−0.25 (-2.24%)
Close on Nov 20, 2026Market cap $99.18MP/E 136.5Yield –
ImmuCell Corp financial ratios
See a number that looks wrong?